Guided home brain stimulation program for menstrual and menopause symptoms
Follows adults using a 12-week guided program for menstrual and menopause mood symptoms.
Plain-language title generated from the registry record
Registry title: CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life
Key facts
- Where
- San Francisco, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07679074, who can take part
Where in United States
- Alethios Digital Research Platform (Decentralized)San Francisco, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Samphire Group, Inc.
- Trial code
- NCT07679074
- Record updated
- 1 July 2026
- Original description
This study evaluates the feasibility and efficacy of the Samphire Guided Care (SGC) programRead full original descriptionShow less
A 12-Week Prospective Cohort Study Evaluating the Efficacy of the Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life in Individuals With Menstrual and Pelvic Health Conditions
This study evaluates the feasibility and efficacy of the Samphire Guided Care (SGC) program
* a 12-week structured digital health program combining clinician-led onboarding, at-home neuromodulation using the Lutea tDCS device, neuromodulation coach support, and app-based symptom tracking - on work productivity, employee wellbeing, and quality of life in individuals experiencing mood and cognitive symptoms associated with menstruation, perimenopause, or menopause.
Inclusion: Self-identified female, aged 18-65 years at the time of enrollment; Basic English literacy; Able and willing to provide informed consent electronically; Residing in the United States; Reporting mood or cognitive symptoms associated with menstruation, perimenopause, or menopause (must endorse a minimum of three of the following: irritability, emotional dysregulation, brain fog, fatigue, reduced concentration, sleep disruption, or low mood); Symptoms present for at least 3 months and sufficiently severe to interfere with daily functioning, work performance, quality of life, or interpersonal relationships; Currently in full-time employment with medical benefits as part of compensation package; Access to a smartphone with internet access compatible with the Samphire mobile application; Able to safely operate the study device in the home environment; Willing to complete baseline, mid-program, and end-of-program questionnaires and engage with the 12-week guided care program.
Exclusion: Current participation in another interventional neurotechnology or drug study; History of epilepsy or seizure disorder; Severe or unstable neurological disease that, in the opinion of the study team, may increase risk or interfere with participation; Active scalp lesions, open wounds, or dermatologic conditions at electrode sites that may interfere with safe device use; Current diagnosis of schizophrenia, bipolar disorder, or other severe psychiatric condition that would make participation inappropriate, as determined by screening; Pregnancy, breastfeeding, or actively planning pregnancy during the study period; Implanted electronic or metal devices in the head, neck, or brain region contraindicated for tDCS use; Active suicidal ideation, recent suicidal behavior, or clinically significant self-injurious behavior, as determined by participant self-report during screening; Inability to provide informed consent or safely use the device in the home environment.